Ehud Marom, Chairman & CEO

Ehud Marom is one of our founders and has served as our chief executive officer and as chairman of our board of directors since our inception in January 2008. Mr. Marom has over 40 years of management and operational experience in the life sciences industry. Prior to our founding, Mr. Marom served in various senior positions at multinational pharmaceutical companies, including as vice president of two divisions at Teva Pharmaceutical Industries Ltd. from 1992 to 1995, where he launched Copaxone (with current sales of $4 billion per year) and was the head of the Copaxone global operation team and headed the global operations of Teva Pharmaceutical Industries Ltd.’s chemical division. From 2000 to 2002, Mr. Marom served as president of Peptor Ltd., where he led the pharmaceutical development of the innovative diabetes product, DiaPep. From 2002 to 2004, Mr. Marom served as chief executive officer of Gamida-Cell Ltd., a stem cell development company. From 2005 to 2007, Mr. Marom served as chief executive officer of Makhteshim, a company with annual sales of $1 billion and the world’s leader in branded off-patent crop protection solutions (which later became Makhteshim-Agan Industries Ltd. and has since been acquired by China National Agrochemical Corporation, a subsidiary of China National Chemical Corporation). Mr. Marom served as vice president of supply of Makhteshim-Agan Industries Ltd. from 2005 to 2009. He currently serves also as the chairman of Pharma Two B and helped guide its product, P2B001 for the treatment of early diagnosed Parkinson disease, through a successful phase IIb pivotal trial expected to be registered via the 505(b)(2) regulatory pathway. Mr. Maron serves as well as chief executive officer and chairman of Stem Cell Medicine Ltd. Ehud has a B.Sc in chemical engineering with honors, from the Technion, Israel.


Itamar Borowitz, PhD

Itamar Borowitz has served as a director since May 2009. In the past, he served as the chief executive officer of Israel’s third largest insurance company, Phoenix Insurance Company Ltd., from 1992 to 2001. This position marked the culmination of his 27 year career within the Phoenix Group, during which he held a variety of senior management positions. Since 2009, Dr. Borowitz has served as the chief executive officer of BIT Enterprises Ltd., an advisor to Generali Financial Holdings – Sub-Fund 2, a Specialised Investment Fund governed by the Luxembourg law of 13 February 2007, which invests, inter-alia, in Israeli hi-tech companies and is a principal shareholder of our company. From 2005 to 2008, Dr. Borowitz served as an advisor to the Post of Israel. Since 2001, Dr. Borowitz serves as a member of the advisory board and a representative to Israel of GLL Real Estate Partners GmBH. Previously, Dr. Borowitz served as the chief executive officer of Dolev Insurance Co. Ltd., as the chairman of the board of directors of Surdam, Lloyd’s agent in Israel, as the chairman of Israel Insurance Association, the chairman of Academic College of Insurance and a director of Mehadrin Ltd., the largest citrus company in Israel. Dr. Borowitz serves as the Chairman of the Board of Inbal Pinto and Avshalom Polak Dance Company. Dr. Borowitz has been serving as a member of the board of governors of the Hebrew University of Jerusalem and of Tel Aviv University for over 20 years, and serves as the chairman of Yissum, the technology transfer company of the Hebrew University. Dr. Borowitz’s academic background includes a PhD in High Energy Physics, an MBA and B.A. in General History from Tel Aviv University, Israel, and a B.Sc. in Mathematics and Physics from the Hebrew University of Jerusalem, Israel. 


Yair Schindel, MD, MBA

Dr. Yair Schindel is Co-Founder & Managing Partner at aMoon Partners, an investment management firm focused on innovative Israeli healthcare and life science ventures. He is also a board member of Pharma Two B and NasVax. Dr. Schindel previously served as CEO, Digital Israel at Israeli Prime Minister’s Office and Co-founder & Board Member of MAOZ a non-profit that advances the common-good and actions towards Israel’s socio-economic resilience among a diverse network of leaders across different sectors and populations groups. He was also CEO of Start-Up Nation Central, Vice President at OmniGuide Inc., and worked at Israel Defense Forces. Dr. Schindel holds an MBA from Harvard University, studied Healthcare/General Management at Harvard Business School, attended Medical School at Ben-Gurion University of the Negev and holds a B.Sc. from Ben-Gurion University of the Negev.


Dov Pekelman, PhD

Dov Pekelman currently serves as the chairman of the special committee of the board of directors of Taro Pharmaceuticals Industries Ltd. (NYSE: TARO), as well as chairman of Atera Networks Ltd. Prof. Pekelman serves on the board of directors of Enzymotec Ltd. (NASDAQ:ENZY) and the Interdisciplinary Center (IDC), Herzliya, Israel and is chairman of the IDC Corporation, the center’s economic arm. From 1985 to 2008, Prof. Pekelman served as a senior consultant to Teva Pharmaceutical Industries Ltd. and also founded and ran a leading, Israeli-based management-consulting firm, P.O.C. Ltd. Previously, he served on the board of directors of several industrial corporations, including Koor Industries Ltd. (TASE: KOR), and was also a member of the advisory committee of the Bank of Israel. He holds a bachelor’s degree from the Technion, Israel Institute of Technology, Haifa, Israel and a doctorate from the University of Chicago.


Adv. Maya Liquornik

Maya Liquornik is a founding member of Meitar Liquornik Geva Leshem Tal, Israel’s largest and leading international law firm. Currently she is of counsel to the firm’s Corporate and Securities Group. Maya represents corporations in a broad range of international and domestic corporate and commercial transactions, with emphasis on mergers and acquisitions, private equity financings, venture capital, information and communications technology transactions, outsourcing and advisory work. Maya has substantial experience in structuring and negotiating complex cross border technology and outsourcing transactions. Her practice focuses on representing large publicly traded corporations, technology companies in various stages of development, venture capital and private equity funds and other corporate and investment banking clients. Prior to joining Meitar, Maya was an associate at Weil, Gotshal & Manges in New York.


Itay Attar, CPA

Itay Attar serves as Portfolio Manager at Crossroad Venture Capital and CFO at Hairstetics. Mr. Attar was previously a Business Consultant in Ernst & Young’s Transaction Advisory Services Division and Financial Analyst at Intel Electronics. He holds a BA in Economics and Accounting and an MA in Economics from Ben Gurion University.